President Trump’s plan to fix IVF might look bold in a headline. In reality, it doesn’t create a single new embryology lab. It doesn’t hire one more specialist. It won’t change the fact that right now, only people with plenty of money can afford IVF, and throwing subsidies at a market that’s already bottlenecked only shifts who pays.
In this episode, we’re joined by Pam Pure, co-founder and CEO of Posterity Health, and Khaled Kteily, founder and CEO of Legacy. They discuss why we should view infertility as a men's issue as well as a women's issue.
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
A new startup named Zuri Fertility recently launched. Its platform provides resources for patients who are trying to conceive — including telehealth, at-home testing, prescriptions, mental health services, education and care coordination.
By augmenting the embryologist in selecting the most viable embryo, there is potential for AI to help a patient conceive in one or two cycles, reducing the inherent cost of IVF therapy, and making the treatment more accessible to diverse populations that often don’t have ease of access to treatments today.
The ability of healthcare providers to leverage accurate, sophisticated and timely diagnostic testing for infertility patients is a crucial part of the patient journey.
Through thoughtful consumer-centric design and application, these digital fertility solutions have the potential to smooth the path towards parenthood for countless couples and individuals around the world.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
The study out of Vanderbilt University Medical Center found 14 percent of individuals with genetic variants impacting the kidney had kidney transplants and 10 percent with another variant had liver transplants. These transplants could have been avoided had the underlying genetic cause been disclosed.
For women either born with no uterus or who have Uterine Factor Infertility, this procedure could make it possible to get pregnant.
23andMe and Celmatix are combining forces to understand the genomic underpinnings of infertility.
TocopheRx is developing an infertility drug that's meant to sidestep IVF injections - converting in vitro fertilization into a completely oral regimen for both men and women. It's raising a $22 million Series A.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
Also, the percentage of adults in the US deemed obese has increased from 32 percent to 38 percent in the 10 years to 2014, according to data from the Centers for Disease Control and Prevention
Although men are the sole cause or a contributing cause in about 40 percent of infertility cases, according to data from the American Society of Reproductive Medicine, men are less likely to seek medical help than women.
Trying to get pregnant is difficult for many women. Just tracking ovulation isn't enough to optimize the success rate of conception.
Pennsylvania upstart Rinovum Women's Health is marketing a cervical cap tool - around for decades - that it says improves conception rates for women that have issues with fertility.
In vitro fertilization is a tough process. Even if a set of embryos are able to form, it’s a real crapshoot to see which – if any – will actually be viable. Bay Area biotech Auxogyn has developed a test to track whether an embryo is developing successfully – and has raised a healthy swath of cash to commercialize its fresh-on-the-market […]